BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30530621)

  • 21. Total synthesis of Le(A)-LacNAc pentasaccharide as a ligand for Clostridium difficile toxin A.
    Zhang P; Ng K; Ling CC
    Org Biomol Chem; 2010 Jan; 8(1):128-36. PubMed ID: 20024143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human intestinal enteroids as a model of
    Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
    [No Abstract]   [Full Text] [Related]  

  • 23. Cellular uptake of Clostridium difficile TcdA and truncated TcdA lacking the receptor binding domain.
    Gerhard R; Frenzel E; Goy S; Olling A
    J Med Microbiol; 2013 Sep; 62(Pt 9):1414-1422. PubMed ID: 23558138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clostridium difficile toxins: more than mere inhibitors of Rho proteins.
    Genth H; Dreger SC; Huelsenbeck J; Just I
    Int J Biochem Cell Biol; 2008; 40(4):592-7. PubMed ID: 18289919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of a neutralizing antibody helps identify structural features critical for binding of
    Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
    J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
    [No Abstract]   [Full Text] [Related]  

  • 26. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area.
    Shin BM; Lee EJ; Kuak EY; Yoo SJ
    Anaerobe; 2009 Dec; 15(6):266-9. PubMed ID: 19772927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
    Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
    BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human α-Defensin-6 Neutralizes
    Barthold L; Heber S; Schmidt CQ; Gradl M; Weidinger G; Barth H; Fischer S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward a structural understanding of Clostridium difficile toxins A and B.
    Pruitt RN; Lacy DB
    Front Cell Infect Microbiol; 2012; 2():28. PubMed ID: 22919620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Processing of Clostridium difficile toxins.
    Giesemann T; Egerer M; Jank T; Aktories K
    J Med Microbiol; 2008 Jun; 57(Pt 6):690-696. PubMed ID: 18480324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.
    Merrigan M; Venugopal A; Mallozzi M; Roxas B; Viswanathan VK; Johnson S; Gerding DN; Vedantam G
    J Bacteriol; 2010 Oct; 192(19):4904-11. PubMed ID: 20675495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.
    Pruitt RN; Chumbler NM; Rutherford SA; Farrow MA; Friedman DB; Spiller B; Lacy DB
    J Biol Chem; 2012 Mar; 287(11):8013-20. PubMed ID: 22267739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of Clostridium difficile toxins to human milk oligosaccharides.
    El-Hawiet A; Kitova EN; Kitov PI; Eugenio L; Ng KK; Mulvey GL; Dingle TC; Szpacenko A; Armstrong GD; Klassen JS
    Glycobiology; 2011 Sep; 21(9):1217-27. PubMed ID: 21610194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate.
    Sturino JM; Pokusaeva K; Carpenter R
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7178-83. PubMed ID: 26149988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemorrhagic toxin and lethal toxin from Clostridium sordellii strain vpi9048: molecular characterization and comparative analysis of substrate specificity of the large clostridial glucosylating toxins.
    Genth H; Pauillac S; Schelle I; Bouvet P; Bouchier C; Varela-Chavez C; Just I; Popoff MR
    Cell Microbiol; 2014 Nov; 16(11):1706-21. PubMed ID: 24905543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection.
    Persson S; Torpdahl M; Olsen KE
    Clin Microbiol Infect; 2008 Nov; 14(11):1057-64. PubMed ID: 19040478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular methods to study transcriptional regulation of Clostridium difficile toxin genes.
    Antunes A; Dupuy B
    Methods Mol Biol; 2010; 646():93-115. PubMed ID: 20597005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
    Peng Z; Simeon R; Mitchell SB; Zhang J; Feng H; Chen Z
    mSphere; 2019 Oct; 4(5):. PubMed ID: 31578248
    [No Abstract]   [Full Text] [Related]  

  • 40. The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A.
    Olling A; Goy S; Hoffmann F; Tatge H; Just I; Gerhard R
    PLoS One; 2011 Mar; 6(3):e17623. PubMed ID: 21445253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.